A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

Summary

The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD). The objectives of this study are to determine the safety, tolerability and levels of SYX-5219 in the blood and urine when SYX-5219 is given in each part of the study (SAD, MAD, Food Effect and Participants with AD).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Moderate to Severe Atopic Dermatitis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 65 years

Sex

All

Healthy volunteers

Accepted

Sponsor

Sitryx Therapeutics Ltd

Last updated on ClinicalTrials.gov

April 30, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites